List of Excipients in Branded Drug DOBUTAMINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
HF Acquisition Co LLC DBA HealthFirst	DOBUTAMINE	dobutamine	51662-1330	DEXTROSE MONOHYDRATE
HF Acquisition Co LLC DBA HealthFirst	DOBUTAMINE	dobutamine	51662-1330	EDETATE DISODIUM
HF Acquisition Co LLC DBA HealthFirst	DOBUTAMINE	dobutamine	51662-1330	HYDROCHLORIC ACID

Generic Drugs Containing DOBUTAMINE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	dobutamine	0143-9141	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	dobutamine	0143-9141	SODIUM HYDROXIDE
Hikma Pharmaceuticals USA Inc	dobutamine	0143-9141	SODIUM METABISULFITE

What are the Most Frequently-Used Excipients in DOBUTAMINE?

# Of NDCs	Excipient
7	HYDROCHLORIC ACID
7	SODIUM HYDROXIDE
7	SODIUM METABISULFITE

Excipient Strategy and Commercial Opportunities for Dobutamine

Last updated: February 26, 2026

What are the primary considerations in excipient selection for dobutamine?

Dobutamine is a synthetic catecholamine used in cardiac decompensation and shock. It is formulated as an injectable solution requiring specific excipient choices to preserve stability, efficacy, and safety.

Key excipients in dobutamine formulations include:

• Acids: Used to adjust pH; hydrochloric acid (HCl) is common.
• Buffers: Acetate buffer maintains pH stability.
• Antioxidants: Sodium bisulfite prevents oxidation of the active ingredient.
• Preservatives: Not typically used due to the need for sterile, preservative-free solutions.
• Solvents: Water for injection dilutes the drug.
• Stabilizers: Sometimes, sodium chloride adjusts tonicity.

Excipient roles:

• pH adjustment: Maintains the drug at a pH of approximately 3.5–4.0 for stability.
• Oxidation prevention: Antioxidants like sodium bisulfite reduce degradation.
• Solubility enhancement: Acidic pH improves solubility.

How do excipient strategies influence formulation stability and bioavailability?

• The acidic pH facilitated by HCl and acetate buffers stabilizes dobutamine against oxidation and degradation.
• Sodium bisulfite minimizes oxidative pathways, extending shelf life.
• Tonicity agents like sodium chloride improve compatibility with intravenous administration.
• Choice of excipients impacts the drug's compatibility with single-dose vials versus continuous infusion systems.

Stability considerations:

• Dobutamine degrades rapidly in alkaline pH.
• Antioxidants prevent oxidation, which can lead to off-odors and potency loss.
• Packaging materials (e.g., glass vials) are chosen to limit adsorption and degradation.

What are the commercial opportunities in excipient optimization?

Patent landscape:

• Companies can patent novel excipient combinations or formulations that enhance stability, extend shelf life, or enable innovative delivery methods.
• Improving excipient purity and sourcing may result in cost advantages.

Formulation innovations:

• Development of preservative-free, ready-to-use preparations target hospital and outpatient markets.
• Liposomal or nanoparticle formulations with specialized excipients could increase bioavailability and reduce side effects.
• Lyophilized formulations with optimized excipients improve shelf life and ease of storage.

Regulatory pathways:

• New excipient components or formulations require bioequivalence and stability data.
• Regulatory acceptance hinges on safety, efficacy, and manufacturing consistency.

Market segmentation:

• Expedited approval processes for modifications (e.g., 505(b)(2) pathway in the U.S.) enable faster entry for improved formulations.
• Focus on hospital and specialty pharmacies offers niche growth.

Supply chain considerations:

• Sourcing high-purity excipients reduces risk of contamination.
• Contract manufacturing organizations (CMOs) can offer scalable, compliant excipient supply chains.

What are potential revenue drivers tied to excipient advancements?

Opportunity	Description	Impact
Novel excipient combinations	Patents covering stabilizers, buffers, or antioxidants	Competitive advantage
Formulation innovations	Preservative-free, sustained-release, or specialty forms	Market differentiation
Lifecycle management	New formulations with extended shelf lives	Revenue stabilization
Regulatory approvals	Fast-track pathways for modified formulations	Faster market entry
Supply chain optimization	Cost savings on high-purity excipients	Increased margins

Conclusion

Excipient strategies centered on stability, safety, and delivery ease are critical for the commercial success of dobutamine. Targeted formulation innovations and supply chain enhancements present opportunities for patent protection, product differentiation, and accelerated market access.

Key Takeaways

• Excipients in dobutamine formulations primarily include acids, buffers, antioxidants, and tonicity agents.
• Optimization of excipient composition enhances stability, shelf life, and administration compatibility.
• Innovation in excipient formulations can enable patent protection, improve patient safety, and open new markets.
• Regulatory pathways support lifecycle management by enabling faster approval of formulation modifications.
• Supply chain robustness ensures product quality and cost efficiency, impacting overall profitability.

FAQs

1. What excipient characteristics are crucial for dobutamine stability?
   pH stabilization, oxidative protection, and compatibility with intravenous delivery.

2. Are there opportunities for patenting excipient-based innovations for dobutamine?
   Yes, especially formulations with novel stabilizers or delivery mechanisms.

3. How do excipient choices impact regulatory approval?
   They influence stability data, safety profiles, and compliance, affecting approval timelines.

4. Can excipient improvements extend dobutamine shelf life?
   Yes, by enhancing oxidative stability and preventing degradation pathways.

5. What market segments benefit most from excipient innovations?
   Hospitals, outpatient infusion centers, and specialty clinics.

References

1. U.S. Food and Drug Administration. (2021). Guidance for Industry: Stability Testing of Drug Substances and Products.
2. European Medicines Agency. (2020). Guideline on the stability testing of medicinal products.
3. Lee, R., & Lee, M. (2019). formulation considerations in intravenous catecholamines. Journal of Pharmaceutical Sciences.
4. Patel, S., et al. (2022). Excipient strategies for injectable drug stability. International Journal of Pharmaceutics.
5. World Health Organization. (2018). Manual for Stability Testing of Pharmaceutical Products.